The $30M private placement is the dominant catalyst, removing near-term going-concern risk and enabling FemBloc clinical advancement, but the core business is deteriorating with declining revenue and rising costs. Watch for updates on FemaSeed commercial adoption and FemBloc FINALE trial enrollment. The financing likely extends the runway into 2027, buying time for catalysts.
Price Chart
Executive Summary
Femasys reported Q2 2026 revenue of $331,827 (down 18.9% YoY) and a net loss of $4,469,095 ($-1.33/share), with no consensus estimates provided for comparison. The quarter was overshadowed by a subsequent $30 million private placement (closing after the period) that provides a cash runway into 2027, but the core business continued to burn cash with only $1.4M in cash on hand at quarter-end. Revenue declined sharply as FemVue sales dropped, while operating expenses rose 28% on higher R&D and sales/marketing costs.
Key Financial Metrics
Key Facts
- Q2 2026 revenue fell 18.9% YoY to $331,827, driven by lower FemVue sales
- Net loss was $4,469,095 ($-1.33/share) vs $4,585,922 ($-3.18/share) in Q2 2025
- Cash at June 30, 2026 was only $1.4M, down from $9.3M at Dec 31, 2025
- Subsequent $30M private placement (up to $90M if warrants exercised) was completed after quarter-end
- Operating expenses rose 28% to $5.26M as R&D spending increased 37.6% for FemBloc clinical costs
- Sales for H1 2026 were essentially flat at $756,716 (up 0.8% YoY)
- Company expects current cash to fund operations into Q3 2026 (pre-private placement)
Financial Impact
Revenue decline of $77,441 vs prior year; net loss of $4.47M; cash burn of ~$7.8M in H1 2026
Risk Factors
- Revenue decline of 18.9% QoQ signals weak commercial traction for core products
- Cash burn rate of ~$3.9M/quarter suggests only ~7 months of runway even after $30M financing
- FemBloc still requires FDA approval with no clear timeline
- Heavily dilutive financing (warrants up to $90M) will overhang the stock
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-033145 |
| Document: ef20080275_8k.htm | 0001140361-26-033145 |
| Document: 0001140361-26-033145-index-headers.html | 0001140361-26-033145 |
| Document: 0001140361-26-033145-index.html | 0001140361-26-033145 |
| Document: 0001140361-26-033145.txt | 0001140361-26-033145 |
| 8-K Data (Synthetic) | 0001140361-26-033145 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | Press Release | $1.67 | awaiting T+5 | — | $1.41 (−15.57%) |
Oct 15, 2026 11d ago | SC 13G | $1.74 $1.56 | ▼ −10.09% | ▼ −9.07% | $1.41 (−18.73%) |
Sep 29, 2026 28d ago | EFFECT | $2.09 $2.08 | ▲ +0.48% | ▲ +2.43% | $1.41 (+32.54%) |
Aug 14, 2026 10w ago | 8-K | $2.16 $2.98 | ▼ −37.96% | ▼ −39.15% | $1.41 (+34.72%) |
Aug 14, 2026 10w ago | Press Release | $2.16 $2.98 | ▲ +37.96% | ▲ +39.15% | $1.41 (−34.72%) |
Aug 11, 2026 10w ago | Insider Cluster | $2.35 $2.71 | ▲ +15.32% | ▲ +15.76% | $1.41 (−40.00%) |
Aug 7, 2026 11w ago | Press Release | $2.66 $2.29 | ▲ +13.91% | ▲ +14.31% | $1.41 (+46.99%) |
Jun 4, 2026 20w ago | 8-K | $7.14 $4.78 | ▼ −33.05% | ▼ −30.50% | $1.41 (−80.25%) |
May 13, 2026 23w ago | 8-K | $7.61 $6.75 | ▼ −11.38% | ▼ −10.66% | $1.41 (−81.48%) |
May 8, 2026 24w ago | 8-K | $8.08 $7.26 | ▼ −10.24% | ▼ −10.16% | $1.41 (−82.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers